Broncus Holding Corporation (HKG:2216)

Market Cap	563.97M +2.2%
Revenue (ttm)	1.35M -97.9%
Net Income	-139.13M
EPS	-0.29
Shares Out	527.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	692,018
Average Volume	492,350
Open	1.030
Previous Close	1.050
Day's Range	1.000 - 1.090
52-Week Range	0.980 - 3.720
Beta	1.18
RSI	35.81
Earnings Date	Aug 28, 2026

About Broncus Holding

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, and internationally. The company offers InterVapor, a thermal vapor treatment system to treat chronic obstructive pulmonary disease (COPD); BroncAblate Radiofrequency Ablation System, a transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation (TLD) Radiofrequency Ablation System for the treatment of COPD; H-Marker, a pulmonary surgical marker can be used...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2012
• Employees: 191
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2216

Financial Performance

In 2025, Broncus Holding's revenue was $174,000, a decrease of -97.86% compared to the previous year's $8.13 million. Losses were -$17.88 million, 16.8% more than in 2024.

Financial numbers in USD